Group 1 - The company currently does not produce glass bottles for photolithography materials [2] - The expansion and renovation project for the annual production of 560 million pre-filled syringes is expected to be completed by the end of 2025 [2] - Further details will be disclosed in the company's announcement on the Shanghai Stock Exchange regarding the completion of certain fundraising projects [2]

Core Viewpoint - Shandong Pharmaceutical Glass (600529.SH) announced the termination of its original controlling shareholder restructuring and finalized a private placement plan to raise 3.235 billion yuan, with the China National Pharmaceutical Group (Sinopharm) set to become the new controlling shareholder, changing the actual controller from the Yiyuan County Finance Bureau of Shandong Province to the State-owned Assets Supervision and Administration Commission of the State Council [1][5][10] Group 1: Company Overview - Shandong Pharmaceutical Glass was established in 1993 with a registered capital of 664 million yuan and is located in Zibo City, Shandong Province [1] - The company is a leading player in the pharmaceutical glass industry, mastering core processes such as borosilicate molded bottles and borosilicate tubes, with product quality at the forefront [1][5] Group 2: Restructuring and Capital Cooperation - The termination of the restructuring was due to a long-anticipated capital cooperation adjustment involving Shandong Luzhong Investment Co., Ltd. (Luzhong Investment), which was the previous controlling shareholder [3][9] - In June 2025, Sinopharm International and its Hong Kong subsidiary signed an investment cooperation agreement with Luzhong Investment, aiming to acquire 51% of Luzhong Investment's shares to indirectly participate in Shandong Pharmaceutical Glass's operations [3][8] Group 3: Private Placement Details - The company plans to issue shares to specific investors to raise no more than 3.235 billion yuan, with a share price set at 16.25 yuan per share, representing 80% of the average stock price over the previous 20 trading days [4][9] - The issuance will not exceed 19,908,420 shares, accounting for 30% of the company's total share capital before the issuance [4][9] Group 4: New Shareholders and Control Changes - The subscribers for the new shares include Sinopharm International and its affiliate Shandong Yaoxin Health Industry Co., Ltd., with Sinopharm International set to acquire 15,607,300 shares and Shandong Yaoxin 4,307,690 shares [4][10] - Post-issuance, Sinopharm International and Shandong Yaoxin will hold a combined 199 million shares, representing 23.08% of the total share capital, making Sinopharm International the controlling shareholder [4][10] Group 5: Future Directions and Funding Utilization - The net proceeds from the fundraising will be used to supplement working capital, focusing on three main development directions: increasing investment in technological innovation, promoting industrial specialization integration, and leveraging Sinopharm International's global network to accelerate international certification processes [5][10] - This collaboration is expected to enhance the company's overall competitiveness and facilitate its transformation into a technology-driven international enterprise [5][10] Group 6: Financial Performance - For the first three quarters of 2025, Shandong Pharmaceutical Glass reported revenue of 3.401 billion yuan, a year-on-year decrease of 11.1%, and a net profit attributable to shareholders of 542 million yuan, down 24.7% [6][11] - As of the end of September 2025, the company's total assets amounted to 9.882 billion yuan, with total liabilities of 1.733 billion yuan and total net assets of 8.149 billion yuan [6][11]

Core Viewpoint - Shandong Pharmaceutical Glass Co., Ltd. plans to issue up to 199,084,233 A-shares at a price of 16.25 yuan per share, aiming to raise no more than 3.235 billion yuan to supplement working capital, with the issuance subject to various approvals [1][4][5]. Company Announcements - The company held its 11th Board of Directors' fifth meeting, approving the proposal for a private placement of shares to China International Pharmaceutical Health Co., Ltd. and Shandong Yaoxin Health Industry Co., Ltd. [1][4]. - The issuance will result in China International becoming the controlling shareholder, with the actual controller changing to China National Pharmaceutical Group, ultimately controlled by the State Council's State-owned Assets Supervision and Administration Commission [2][6]. Financial Details - The total market capitalization of Shandong Pharmaceutical Glass is currently 13.996 billion yuan, ranking 22nd in the medical device sector and 1495th in the A-share market [1]. - The company reported that the net proceeds from the previous fundraising amounted to 1.842 billion yuan, which was fully utilized for specific projects, with a remaining balance of approximately 769.76 million yuan for future project construction [3]. Shareholder Changes - The original controlling shareholder, Luzhong Investment, will see its shareholding decrease from 19.50% to 15.00% following the issuance [4][6]. - After the issuance, the combined shareholding of China International and Shandong Yaoxin will be 23.08%, leading to a change in control [2][7]. Compliance and Governance - The company has confirmed that there are no commitments to guarantee returns to the issuance targets, nor any financial assistance provided to them [2]. - The independent directors have stated that the issuance plan complies with legal regulations and does not harm the interests of minority shareholders [5][7].

山东省药用玻璃股份有限公司 详式权益变动报告书 上市公司名称：山东省药用玻璃股份有限公司 股票简称：山东药玻 股票代码：600529 股票上市地点：上海证券交易所 信息披露义务人一：中国国际医药卫生有限公司 住所及通讯地址：北京市朝阳区惠新东街 4 号 信息披露义务人二：山东耀新健康产业有限公司 住所及通讯地址：山东省淄博市沂源县历山街道办事处兴源路 66 号沂源经济开 发区创业大厦 2 号楼 303 室 股份变动性质： 权益变动（增加） 签署日期：二〇二六年一月 四、本次权益变动尚需山东药玻股东会批准、淄博市国有资产监督管理机 构和国务院国资委批准、本次权益变动涉及的经营者集中事项通过国家市场监 督管理总局国家反垄断局审查（如需）、本次权益变动涉及的山东药玻股份发 行事项获得上交所审核通过及证监会同意注册的批复等。 五、本次权益变动是根据本报告书所载明的资料进行的。除信息披露义务 人和所聘请的专业机构外，没有委托或者授权任何其他人提供未在本报告书中 列载的信息和对本报告书做出任何解释或者说明。 六、根据《上市公司收购管理办法》的规定，本次权益变动未触发要约收 购义务。 1 山东省药用玻璃股份有限公司 详式权 ...

中信证券股份有限公司 关于 山东省药用玻璃股份有限公司 详式权益变动报告书 之 财务顾问核查意见 财务顾问 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司收 购管理办法》《公开发行证券的公司信息披露内容与格式准则第15号——权益 变动报告书》《公开发行证券的公司信息披露内容与格式准则第16号——上市 公司收购报告书》及相关法律、法规的规定，中信证券股份有限公司按照证券 行业公认的业务标准、道德规范和勤勉尽责精神，就本次信息披露义务人披露 的《山东省药用玻璃股份有限公司详式权益变动报告书》进行核查，并出具核 查意见。 为使相关各方恰当地理解和使用本核查意见，本财务顾问特别声明如下： （广东省深圳市福田区中心三路8号卓越时代广场（二期）北座） 二〇二六年一月 | क्रिया | | --- | | 财务顾问意见 43 | | --- | 中信证券股份有限公司关于山东省药用玻璃股份有限公司详式权益变动报告书之财务顾问核查意见 声明 1、本财务顾问已按照规定履行了尽职调查义务，对信息披露义务人披露的 《山东省药用玻璃股份有限公司详式权益变动报告书》进行了核查，确信内容 与格式符合规定，并保证所发表的 ...

山东省药用玻璃股份有限公司 未来三年（2026-2028 年）股东回报规划 为完善和健全山东省药用玻璃股份有限公司科学、持续、稳定的分红决策和 监督机制，积极回报投资者，引导投资者树立长期投资的理性投资理念，根据中 国证监会《关于进一步落实上市公司现金分红有关事项的通知》（证监发[2012]37 号）、《上市公司监管指引第 3 号—上市公司现金分红》（证监会公告[2013]43 号） 等法律法规的相关要求和《山东省药用玻璃股份有限公司章程》（以下简称"《公 司章程》"）的规定，公司董事会结合公司实际情况经过专项研究论证，制订了未 来三年（2026 年-2028 年）股东回报规划（以下简称"本规划"），具体内容如下： 一、制定股东回报规划考虑因素 公司着眼于长远和可持续发展，综合考虑经营发展规划、股东意愿与要求、 现金流量状况、外部融资环境及资本成本，建立对投资者持续、稳定、科学的回 报规划与机制，从而对利润分配做出制度性安排，以保证利润分配政策的连续性 和稳定性。 二、本规划的制定原则 股东回报规划的制定应符合相关法律法规、规范性文件的规定，应重视对投 资者的合理投资回报并兼顾公司当年的实际经营情况和可持续发 ...

Core Viewpoint - China National Pharmaceutical Group (国药集团) is steadily advancing its acquisition of Shandong Pharmaceutical Glass (山东药玻), a leading company in the domestic pharmaceutical glass industry, through a private placement plan to raise up to 3.235 billion yuan [1][2]. Group 1: Acquisition Details - Shandong Pharmaceutical Glass plans to issue up to 1.99 million shares at a price of 16.25 yuan per share, raising no more than 3.235 billion yuan, with China International Pharmaceutical Co. and its subsidiary subscribing to the shares [3][6]. - Following the completion of this issuance, China International will become the controlling shareholder of Shandong Pharmaceutical Glass, with the actual controller changing to China National Pharmaceutical Group [3][6]. - The previous plan for indirect restructuring through Shandong Luzhong Investment was abandoned due to various factors, leading to a direct capital injection approach [2][3]. Group 2: Financial Performance - In the first three quarters of 2025, Shandong Pharmaceutical Glass reported revenue of 3.401 billion yuan, a year-on-year decrease of 11.1%, and a net profit attributable to shareholders of 542 million yuan, down 24.7% [5][6]. - Despite the decline in performance, the company's gross profit margin improved to 33.08%, an increase of 0.98 percentage points year-on-year [5][6]. Group 3: Strategic Implications - The acquisition aims to enhance the research and innovation capabilities of Shandong Pharmaceutical Glass, allowing for increased investment in new technologies and products, thereby strengthening its market position [1][6]. - The partnership with China National Pharmaceutical Group will facilitate better resource accumulation in pharmaceutical research, industrial manufacturing, and global network layout, contributing to the development of China's biopharmaceutical and innovative drug sectors [4][6]. - Shandong Pharmaceutical Glass is recognized as a national manufacturing champion, actively engaging in key research and development projects, and has accumulated a total of 291 authorized patents, including 40 invention patents [6][7].

Core Viewpoint - Shandong Pharmaceutical Glass Co., Ltd. plans to issue up to 199,084,233 A-shares at a price of 16.25 yuan per share, aiming to raise no more than 3.235 billion yuan to supplement working capital, with a change in control to China National Pharmaceutical Group Corporation [2][4][6] Trading Information Summary - As of January 14, 2026, Shandong Pharmaceutical Glass closed at 21.0 yuan, up 2.24%, with a turnover rate of 4.63%, trading volume of 307,500 shares, and a transaction amount of 645 million yuan [1] - On the same day, the net inflow of main funds was 9.6426 million yuan, accounting for 1.5% of the total transaction amount, while retail investors had a net outflow of 1.5527 million yuan, accounting for 0.24% [2] Company Announcement Summary - The company’s board approved a proposal to issue shares to specific entities, which requires further approval from the shareholders' meeting, state-owned asset regulatory authorities, the Shanghai Stock Exchange, and the China Securities Regulatory Commission [2][4] - The issuance will result in a change of control, with China National Pharmaceutical Group becoming the actual controller, and the original controlling shareholder, Luzhong Investment, terminating its cooperation with China National Pharmaceutical International on January 11, 2026 [3][6] - The company has committed not to provide financial assistance or guarantees to the issuing entities and has acknowledged the potential dilution of immediate returns from this issuance [4][5] Financial and Operational Insights - The company’s previous fundraising net amount was approximately 1.842 billion yuan, with 1.141 billion yuan invested by September 30, 2025, and the investment progress is reported as normal [4][5] - The company expects to have daily related transactions with China National Pharmaceutical Group totaling 46.7 million yuan in 2026, primarily for the sale of pharmaceutical glass packaging materials [5] - The feasibility analysis report indicates that the raised funds will be used entirely to supplement working capital, enhancing capital strength, research innovation capabilities, and risk resistance [5][6]

Core Viewpoint - Shandong Pharmaceutical Glass (山东药玻) has terminated its restructuring plan with its controlling shareholder, but China National Pharmaceutical Group (国药集团) remains interested and will directly invest in the company through a private placement to become the controlling shareholder [1][2]. Group 1: Investment and Financing - Shandong Pharmaceutical Glass plans to raise up to 3.235 billion yuan through a private placement, with the net proceeds intended to supplement working capital [1]. - After the issuance, China International Pharmaceutical Co., Ltd. (国药国际) and Shandong Yaoxin Health Industry Co., Ltd. (山东耀新) will collectively hold 199 million shares, representing 23.08% of the total share capital, making国药国际 the controlling shareholder [1]. Group 2: Business Performance and Strategy - Shandong Pharmaceutical Glass is a leading company in the domestic pharmaceutical glass industry, with core processes in borosilicate molded bottles and borosilicate tubes [3]. - The company aims to enhance its research and innovation capabilities and product offerings in high-end pharmaceutical packaging materials, addressing gaps compared to international peers [3]. - For the first three quarters of 2025, Shandong Pharmaceutical Glass reported revenue of approximately 3.401 billion yuan, a year-on-year decrease of 11.1%, and a net profit of about 542 million yuan, down 24.7% year-on-year, attributed to declining revenue and increased inventory impairment losses [3]. Group 3: Industry Implications - The change in ownership is seen as a strategic move to strengthen the pharmaceutical supply chain and enhance the integration of the pharmaceutical industry, signaling a key moment for industry consolidation [4].

Core Viewpoint - Shandong Pharmaceutical Glass (山东药玻) has terminated its restructuring plan with its controlling shareholder after over a year of planning, but China National Pharmaceutical Group (国药集团) remains interested and will instead invest directly in the company through a private placement. Group 1: Fundraising and Shareholding Structure - The company plans to raise no more than 3.235 billion yuan through a private placement, with the net proceeds intended to supplement working capital [1] - The issuance will involve China International Pharmaceutical Health Co., Ltd. (国药国际) and Shandong Yaoxin Health Industry Co., Ltd. (山东耀新), with the latter being a wholly-owned subsidiary of 国药国际 [2] - After the issuance, 国药国际 and 山东耀新 will collectively hold 199 million shares, representing 23.08% of the total share capital, making 国药国际 the controlling shareholder [2] Group 2: Termination of Previous Restructuring Plan - The termination of the restructuring plan was due to the complexity of the involved parties and changes in the market environment since the initial planning [3] - The decision was made after friendly consultations among the parties involved, and there are no disputes or other agreements related to the investment cooperation [3] Group 3: Company Performance and Market Position - Shandong Pharmaceutical Glass is a leading company in the pharmaceutical glass industry in China, specializing in core processes such as borosilicate molded bottles and borosilicate tubes [3] - The company reported a decline in revenue and net profit for the first three quarters of 2025, with revenue of approximately 3.401 billion yuan, down 11.1% year-on-year, and net profit of about 542 million yuan, down 24.7% year-on-year [5] - The decline in performance is attributed to decreased revenue, increased inventory impairment losses, and rising management expenses [6] Group 4: Strategic Goals and Future Outlook - The fundraising aims to enhance the company's research and innovation capabilities and increase investment in new technologies and products [4] - The collaboration with 国药集团 is expected to help Shandong Pharmaceutical Glass overcome performance and development bottlenecks, while also strengthening the self-sufficiency of the pharmaceutical supply chain in China [6]